Harvard Bioscience
HBIO
HBIO
65 hedge funds and large institutions have $127M invested in Harvard Bioscience in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
4% less funds holding
Funds holding: 68 → 65 (-3)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
Holders
65
Holding in Top 10
2
Calls
$8K
Puts
$2K
Top Buyers
| 1 | +$2.04M | |
| 2 | +$1.45M | |
| 3 | +$930K | |
| 4 |
CWA
CM Wealth Advisors
Beachwood,
Ohio
|
+$831K |
| 5 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$770K |
Top Sellers
| 1 | -$840K | |
| 2 | -$835K | |
| 3 | -$367K | |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$301K |
| 5 |
Two Sigma Investments
New York
|
-$257K |